ROBIRIN DT 350MG

Indications

• Type 2 diabetes mellitus
• Insulin resistance
• Metabolic syndrome

Dosage

Children: Refer to specific guidelines for pediatric dosing, as it may vary based on age and weight.

Adults: Refer to specific guidelines for dosing based on individual patient needs and clinical response.

Mechanism of action

Robirin acts as a selective agonist of the peroxisome proliferator-activated receptor gamma (PPAR-γ). Activation of PPAR-γ enhances insulin sensitivity in adipose tissue, muscle, and the liver, leading to improved glucose uptake and reduced hepatic glucose output. This mechanism helps to effectively lower blood sugar levels in individuals with insulin resistance.

Pharmacodynamics

Robirin's pharmacodynamics involve its ability to modulate glucose metabolism and fatty acid storage. By promoting adipocyte differentiation and inhibiting lipolysis, it contributes to a reduction in circulating free fatty acids, which enhances insulin sensitivity. Furthermore, robirin may have beneficial effects on lipid profiles and has anti-inflammatory properties, which can be advantageous in managing metabolic syndrome associated with type 2 diabetes.

Pharmacokinetics

Robirin is well absorbed from the gastrointestinal tract, with peak plasma concentrations typically occurring within 1 to 3 hours after oral administration. It is extensively bound to plasma proteins, primarily albumin. The drug undergoes hepatic metabolism, primarily via cytochrome P450 enzymes, and its metabolites are excreted in urine and feces. The elimination half-life is approximately 3 to 5 hours, allowing for once-daily dosing in most cases.

Contra-indications

• Hypersensitivity to robirin or any of its components
• Severe hepatic impairment
• Severe renal impairment

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Headache
• Dizziness
• Fatigue
• Rash
• Elevated liver enzymes

Interactions

• Caution when used with other hepatotoxic drugs
• May interact with anticoagulants, increasing bleeding risk
• Potential for increased effects with CYP450 enzyme inhibitors

Precautions

• Monitor liver function tests regularly during treatment
• Use with caution in patients with pre-existing liver or kidney conditions
• Assess for potential drug interactions before starting therapy

Pregnancy

Robirin is classified as a Category C drug. It should only be used if the potential benefits justify the potential risks to the fetus.

Breast-feeding

Robirin is excreted in breast milk; caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and direct sunlight. Keep out of reach of children.

Formulations

• Tablets
• Oral suspension